医学
免疫疗法
微卫星不稳定性
生物标志物
肿瘤科
重症监护医学
免疫系统
内科学
免疫学
生物
生物化学
微卫星
基因
等位基因
作者
Martina Catalano,Luigi Francesco Iannone,Gabriella Nesi,Stefania Nobili,Enrico Mini,Giandomenico Roviello
标识
DOI:10.1016/j.critrevonc.2023.104135
摘要
Immunotherapy profoundly changed oncology treatment, becoming one of the main therapeutical strategies. Remarkable improvement has been achieved in survival outcomes, but the percentage of patients who benefit from immunotherapy is still limited. Only one-third of patients receiving immune checkpoint inhibitors (ICIs) achieve long-term response. Several patients are not responsive to treatment or relapse after an initial response. To date, programmed death-ligand 1, microsatellite instability, and tumor mutational burden are the three biomarkers validated to predict the ICIs response, but a single variable seems still insufficient in the patient’s selection. Considering the substantial and increasing use of these drugs, the identification of new predictive biomarkers of ICI response is of paramount importance. We summarize the state of the art and the clinical use of immune biomarkers in oncology, highlighting the strength and weaknesses of currently approved biomarkers, describing the emerging tissues and circulating biomarkers, and outlining future perspectives.
科研通智能强力驱动
Strongly Powered by AbleSci AI